

INFORMATION DISCLOSURE STATEMENT

In order to ensure compliance with applicants' duty of disclosure under 37 C.F.R. §1.56 and §1.97(a)-(d), applicants request that the following references be considered and made of record in the above-identified application.

1. PCT International Publication No. WO 97/10211, published 03/20/1997 (Sanofi Bichon);
2. European Application No. EP 0673928A, published 09/27/1995 (Sanofi);
3. US Patent No. 5,434,158, issued on 07/18/1995 (Shah Shrenik, et al.);
4. European Application No. EP 0068999A, published 01/05/1983 (Fabre SA Pierre);
5. Bonnaud, B. et al. (1987) "1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants", *Journal of Medicinal Chemistry*; 30(2): 318-325; and
6. PCT International Publication No. WO 03/051869, published 06/26/2003 (Bang Noergaard, et al.).

Pursuant to M.P.E.P. §609, applicants note that "Where the information listed (in an Information Disclosure Statement) is not in the English language, but was cited in a search report or other action by a foreign patent office in a counterpart foreign application, the requirement for a concise explanation of relevance can be satisfied by submitting an English-language version of the search report or action which indicates the degree of relevance found by the foreign office."

The above-listed references 1-6 were cited in the International Search Report issued November 4, 2004 in connection with PCT/DK2004/000538. A copy of the International Search Report is attached hereto.


C.F.R. §1.98(a)(2)(i) has been amended to eliminate the requirement in paragraph (a)(2)(i) for a copy of each U.S. patent or U.S. patent application publication listed in an IDS in a patent application regardless of the filing date of the application. Accordingly, a copy of reference 3 is not enclosed herewith. Copies of references 1, 2, 4, 5 and 6 are enclosed.

It is respectfully requested that the Examiner consider the cited references and that copies of enclosed Form PTO/SB/08a and Form PTO/SB/08b be initialed and returned indicating that such information has been considered. Applicants respectfully request that the Examiner make the cited references of record in the subject application.

If a telephone interview would be of assistance in advancing prosecution of the above-identified application, applicants' undersigned attorney invites the Examiner to telephone the number provided below.

No fee, other than the enclosed \$5800.00 filing fee for the subject application, is deemed necessary in connection with filing this Preliminary Amendment and Information Disclosure Statement. However, if an additional fee is required, authorization is hereby given to charge this fee, and any other fees not covered by the enclosed check to Deposit Account Number 503201.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Stephen G. Kalinchak", written over a horizontal line.

Stephen G. Kalinchak
Registration No. 38,747
Lundbeck Research USA, Inc.
215 College Road
Paramus, New Jersey 07652
(201) 350-0781 (phone)
(201) 225-9571 (fax)

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.